Sep 14 2009
avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced today the launch of a major Internet marketing program.
To broaden its on line marketing, AVVH signed an agreement with Online Performance Marketing, LP (OPM), a leader in Internet marketing. OPM will promote Neuroskin® Psoriasis Relief on major search engines such as Google®, Yahoo® and Bing®, as well as on numerous health and wellness sites using a variety of specialized methods.
“With Online Performance Marketing’s proven marketing program, we are looking forward to a highly successful campaign that will drive online customer acquisitions at a very reasonable cost,” stated Lorie Campbell-Farley, President and COO. “Our internet marketing program is a partner to our DRTV commercials. We expect as strong or even stronger results from our internet campaign as we do from DRTV.”
A recent study by comScore, Inc. shows that online advertising of consumer products may increase sales more quickly and at a higher rate than comparable TV advertising. With that in mind AVVH wants to capture their share of the over 225 million internet users in the United States (according to Neilson Online). avVaa World Health Care Products, Inc. is positioned to capitalize on America’s growing demand for 24/7 online shopping. The company expects to expand both brand recognition and continuity of sales.
“We have now put together all the elements that are needed to grow our products and sales pipeline as never before,” said Mrs. Campbell-Farley. “We plan to dominate the skin care market. Neuroskin® Psoriasis Relief is a very unique product, being OTC, FDA compliant, steroid free, and having a spray application. Consumer demand is high for a product that can deliver long-term relief from psoriasis and seborrheic dermatitis, our Neuroskin® fills that niche.”
According to a report from market research company Kalorma Information, the market for psoriasis products, currently nearly 7 billion dollars, is predicted to surpass 9 billion by 2016, with 8.5 million people affected with some form of the disease. This, along with psoriasis often being considered ‘second string’ by many pharmaceutical companies, results in a strong window of opportunity for Neuroskin Psoriasis Relief and future avVaa product launches.